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Hexavalent vaccinea b s t r a c t
A hexavalent vaccine containing diphtheria toxoid, tetanus toxoid, whole cell pertussis, Haemophilius
influenza type B, hepatitis B and inactivated polio vaccine (IPV) may: (i) increase the efficiency of vacci-
nation campaigns, (ii) reduce the number of injections thereby reducing needlestick injuries, and (iii)
ensure better protection against pertussis as compared to vaccines containing acellular pertussis anti-
gens. An approach to obtain a hexavalent vaccine might be reconstituting lyophilized polio vaccine
(IPV-LYO) with liquid pentavalent vaccine just before intramuscular delivery. The potential limitations
of this approach were investigated including thermostability of IPV as measured by D-antigen ELISA
and rat potency, the compatibility of fluid and lyophilized IPV in combination with thimerosal and thi-
merosal containing hexavalent vaccine.
The rat potency of polio type 3 in IPV-LYO was 2 to 3-fold lower than standardized on the D-antigen
content, suggesting an alteration of the polio type 3 D-antigen particle by lyophilization. Type 1 and 2
had unaffected antigenicity/immunogenicity ratios. Alteration of type 3 D-antigen could be detected
by showing reduced thermostability at 45 C compared to type 3 in non-lyophilized liquid controls.
Reconstituting IPV-LYO in the presence of thimerosal (TM) resulted in a fast temperature dependent
loss of polio type 1-3 D-antigen. The presence of 0.005% TM reduced the D-antigen content by 20%
(polio type 2/3) and 60% (polio type 1) in 6 h at 25 C, which are WHO open vial policy conditions.
At 37 C, D-antigen was diminished even faster, suggesting that very fast, i.e., immediately after prepa-
ration, intramuscular delivery of the conceived hexavalent vaccine would not be a feasible option. Use
of the TM-scavenger, L-cysteine, to bind TM (or mercury containing TM degradation products), resulted
in a hexavalent vaccine mixture in which polio D-antigen was more stable.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Combination vaccines are very successful, especially for deliv-
ery in children. The inclusion of multiple vaccine antigens in a sin-
gle formulation reduces the number of injections, facilitates
inclusion of new vaccines and increases coverage of routine pedi-
atric immunization programs. For example, the use of pentavalent
vaccine combining diphtheria-tetanus-pertussis (DTP), Hae-
mophilus influenzae type B (Hib) and hepatitis B (HBV) antigens
has raised the coverage of Hib and hepatitis B in the poorest devel-
oping (Gavi-supported) countries [1].One of the challenges for an IPV-containing hexavalent vaccine
is the presence of the preservative thimerosal (TM). TM negatively
affects the antigenicity and immunogenicity of IPV [2] and is used
in the production process of whole cell pertussis (wP) vaccine as an
inactivating agent as well as a preservative [3]. Hence, pentavalent
vaccine contains trace amounts of TM (60.01% (w/v)).
Currently, the globally marketed IPV-containing hexavalent
pediatric combination vaccines (Infanrix Hexa (GSK) and Hex-
axim (Sanofi Pasteur)) contain an acellular pertussis (aP) compo-
nent, which is devoid of TM. The use of wP in hexavalent vaccines
intended for developing countries is important because of the lower
costs and emerging doubts about the long-term effectiveness of aP
vaccines. Unfortunately, no hexavalent combinations with wP
(without TM) are licensed or in late-stage development [1].
The aim of this study is to investigate whether IPV-LYO, as pre-
viously developed [4], could be used in combination with a wP-
containing pentavalent vaccine to generate a concept hexavalent
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tuting IPV-LYO with pentavalent vaccine no substantial change in
total volume is anticipated, likely the same injection volume for
IM-injection may be used.
This study addresses the (thermo)stability of IPV-LYO with
respect to both D-antigenicity and immunogenicity (rat potency)
and shows D-antigenicity data on IPV-LYO reconstituted with a
pentavalent vaccine (DTwP-Hib-HBV).2. Materials and methods
2.1. Materials
The IPV used in this study is a ten times concentrated trivalent
bulk containing the inactivated Mahoney (type 1), MEF (type 2)
and Saukett (type 3) strains at a nominal D-antigen content
(expressed in D-units, DU) of 400-80-320 DU/mL (for types 1, 2
and 3, respectively) and produced under cGMP conditions accord-
ing to a routine production process [5]. The pentavalent vaccine,
Diphtheria, Tetanus, (whole cell) Pertussis, Hepatitis B and Heamo-
philus influenza type b Conjugate Vaccine Adsorbed, was a gift from
Serum Institute of India (SII).
D-sorbitol, magnesium chloride hexahydrate (MgCl26H20) and
monosodium glutamate monohydrate were from Sigma-Aldrich
(St. Louis, MO). Citric acid (Sigma-Aldrich, St. Louis, MO) and dis-
odium hydrogen phosphate (Fluka, Buchs, Switzerland) were used
to prepare McIlvaine buffer. Thimerosal (TM) and L-cysteine were
from Sigma-Aldrich (St. Louis, MO). All excipients used were of
reagent quality or of a higher grade.2.2. Methods
2.2.1. Formulating IPV
Unless indicated otherwise, the trivalent IPV bulk material was
dialyzed against 10 mM McIlvaine buffer (pH 7.0) using a low-
binding regenerated cellulose membrane dialysis cassette (Mw
cut-off = 10 kDa). The dialyzed IPVwas diluted 1:1with formulation
buffer containing: D-sorbitol (20% w/v), MgCl26H20 (17% w/v),
and monosodium glutamate monohydrate (17% w/v) in McIlvaine
buffer (10 mM, pH 7.0). This formulated IPVwas used for the prepa-
ration of IPV-LYO. Liquid IPV was prepared by 1:1 dilution of (not
dialyzed) trivalent IPVwith ultrapurewater. This material was used
as a control in experiments.2.2.2. Lyophilization
Injection vials (3 mL, Aluglas BV, Uithoorn, The Netherlands)
were filled with 0.2 mL of the formulated IPV and half-stoppered
with pre-dried (overnight at 105 C) 13 mm lyophilization stop-
pers (PH21/50 from Aluglas BV, Uithoorn, The Netherlands). Vials
were loaded on precooled shelves (50 C) and the solidified mate-
rial was subsequently lyophilized. Primary drying was done at
0.045 mbar and 45 C for 26 h. Secondary drying was done at a
pressure of 0.01 mbar and shelf temperature that increased from
45 C to 25 C in 13.3 h. Thereafter, both shelf temperature
(25 C) and pressure (0.01 mbar) were kept constant for 24 h. After
lyophilization, vials were closed under vacuum, sealed with alu-
caps and stored for stability testing.2.2.3. Stability testing
For stability studies, liquid IPV (0.2 mL in stoppered and capped
3 mL injection vials) and IPV-LYO (in stoppered and capped 3 mL
vials) were incubated at 2-8, 25, 37, and 45 C. After various peri-
ods of time, vials were taken for analysis.2.2.4. Effect of thimerosal
The effect of thimerosal (TM) on liquid IPV was studied by dilut-
ing trivalent IPV 10-fold with a solution of TM in ultrapure water.
IPV-LYO was reconstituted either with ultrapure water (0.5 mL),
0.5 mL TM solution, or 0.5 mL pentavalent SII-vaccine containing
0.005% (w/v) TM. Final TM concentrations were 0.005 and 0.01%
(w/v).
The possible neutralizing effect of L-cysteine on TM was inves-
tigated by pre-incubating pentavalent vaccine for one hour with
0.05% (w/v) L-cysteine or ultrapure water as negative control. Sub-
sequently, IPV-LYO was reconstituted with the pre-incubated pen-
tavalent vaccines or with ultrapure water as a control. D-antigen
recoveries were determined directly after mixing or after subse-
quent storage at 37 C for 24 h.
2.2.5. Analysis
2.2.5.1. D-antigen ELISA. The D-antigen ELISA was performed as
described elsewhere [6]. Microtiter plates were coated with
serotype-specific bovine anti-polio serum (Bilthoven Biologicals,
Bilthoven, The Netherlands). After washing, dilutions of IPV (recon-
stituted IPV-LYO or liquid) were added. After an incubation period
of 30 min at 37 C under gentle shaking, plates were washed. Sub-
sequently, a mixture of serotype-specific anti-poliovirus mono-
clonal antibody (3-4E4, 3-14-4 and 1-12-9 for type 1, 2 and 3,
respectively) and HRP-labeled anti-mouse IgG (GE Healthcare,
Buckinghamshire, UK) was added and plates were incubated for
30 min. at 37 C while shaking. Subsequently, plates were washed
followed by addition of ELISA HighLight signal reagent
(ZomerBloemen BV, Zeist, The Netherlands). Chemiluminescence
was measured for 10–15 min by using a luminometer (Berthold
Centro LB960). The signal at maximum intensity was used to calcu-
late the D-antigen content relative to the reference standard.
2.2.5.2. Biosensor analysis. Antigenicity was also measured using a
Biacore T200 (GE Healthcare, Hoevelaken, The Netherlands),
equipped with an anti-polio biosensor as described elsewhere
[7]. Goat anti-mouse IgG Fc-specific (Thermo Fisher Scientific Inc,
Waltham, MA), antibodies were covalently immobilized on the
dextran layer of a CM3 sensorchip (GE Healthcare, Hoevelaken,
The Netherlands) by primary amine coupling, following the manu-
facturers recommendations (GE Healthcare, Hoevelaken, The
Netherlands). Serotype-specific monoclonal antibodies (3-4E4
(antigenic site 1, type 1), 3-14-4 (antigenic site 1, type 2),
Hyb300-06 (antigenic site 1, type 3) and 1-12-9 (antigenic site
2/3/4, type 3) were bound to the sensor, followed by IPV. The sen-
sor chip was regenerated with 10 mM glycine-HCl (pH 1.5). Assay
data were analyzed by four-parameter curve fitting using the Bia-
core T200 evaluation software. Antigenicity was calculated relative
to the international reference PU91-01.
2.2.5.3. Rat potency. Immunogenicity of IPV-LYO was measured in
the rat potency test performed as described earlier [7] with the
exception that the highest dilution of the vaccine was not included.
Animal experiments were conducted in accordance with the guide-
lines provided by the Dutch Animal Protection Act, and were
approved by the Committee for Animal Experimentation of Intra-
vacc. RIVM-TOX rats were immunized with four threefold dilutions
of reconstituted IPV-LYO, the liquid IPV control, and the reference
vaccine (PU91-01). After three weeks, sera were collected and neu-
tralizing antibodies against all three poliovirus types were mea-
sured separately by inoculating Vero cells with 100 TCID50 of the
wild-type strains (Mahoney, MEF-1 and Saukett) as described pre-
viously [8]. Two-fold serial serum dilutions were made and serum/
virus mixtures were incubated for three hours at 36 C and 5% CO2
followed by overnight incubation at 5 C. Subsequently, Vero cells
were added and after 7 days of incubation at 36 C and 5% CO2 the
4574 H. Kraan et al. / Vaccine 34 (2016) 4572–4578plates were stained and fixed with crystal violet and the results
were read macroscopically. Virus-neutralizing (VN) titers were
expressed as the last serum dilution that has an intact monolayer
(no signs of cytopathogenic effect). Immunogenicity was expressed
in two ways: (A) as the relative potency to the reference vaccine
using the parallel-line model, and (B) as the average virus-
neutralizing antibody endpoint titer at the second (1/15 dilution)
or third (1/45 dilution) highest vaccine dose.2.2.5.4. Moisture content analysis. Residual moisture content was
determined using a Karl Fischer Coulometer C30 (Mettler-Toledo,
Tiel, The Netherlands) according to the literature [4]. Samples were
weighed, reconstituted in Hydranal Coulomat A (Fluka, Buchs,
Switzerland), and injected into the titration vessel. The empty vials
were weighed and water content was calculated based on the mea-
sured water content, the weight of the lyophilized product in the
vial, the reconstitution volume of the reagent, the titration volume,
and the water content of the blank titration.2.2.5.5. Statistical analysis. For comparative analysis of immuno-
genicity, data were tested by one-way analysis of variance
(ANOVA) followed by a Bonferonni test for multiple comparisons.
Probability (p) values <0.05 were considered significant. All statis-
tical analyses were performed using GraphPad Prism version 6.0
(GraphPad Software Inc., La Jolla, CA).Table 1
Characterization of two IPV-LYO batches that were used for further stability testing. D-anti
both batches were determined. Mean values and SD are shown (n = 3). Rat potency of batch
confidence intervals (CI)) are shown.
IPV-LYO RMC (%) Type 1
Batch 1 8.9 ± 0.4
Composition (DU/mL) – 180 ± 16
D-antigen recovery (%) – 83 ± 7
Batch 2 8.0 ± 0.3
Composition (DU/mL) – 155 ± 2
D-antigen recovery (%) – 80 ± 1






































Fig. 1. Mean virus-neutralizing (VN) titers of serum from rats (n = 10) immunized with 1/
or IPV-LYO (in red) directly after preparation or after subsequent two weeks storage
(diamonds) were shown. Mean values were depicted as horizontal line and error bars sh
between groups (*p < 0.01, **p < 0.001, ***p < 0.0001).3. Results
3.1. Immunogenicity of IPV-LYO
Two batches of IPV-LYO were prepared, characterized and used
for further experiments. The D-antigen composition, D-antigen
recovery, and RMC (see Table 1), and thermostability (data not
shown) of both batches were comparable. Immediately after
lyophilization, the rat potency of IPV-LYO was 0.88, 1.17 and
0.39, respectively for polio type 1, 2 and 3. The rat potency of type
3 was lower than anticipated as based on: (A) the D-antigen con-
centration, and (B) historical data of polio containing vaccines
(data not shown). Virus-neutralizing (VN) titers of polio type 3
were significantly lower in rats immunized with IPV-LYO if com-
pared to liquid IPV (see Fig. 1A). This unanticipated result was con-
firmed with an independent IPV-LYO preparation and throughout
subsequent experiments (see Section 3.2).
In an earlier study it was demonstrated that disruption of anti-
genic site 1 diminished the rat potency of polio type 3 [9]. How-
ever, Biosensor analysis showed that antigenic site 1 remained
intact after freeze-drying, as observed D-antigen concentrations
were 130 ± 5 DU/mL (IPV-LYO) and 137 ± 1 DU/mL (liquid IPV).3.2. Stability of IPV-LYO
Accelerated stability testing for two weeks at 45 C, showed sig-
nificantly higher VN-titers for all three serotypes in IPV-LYO when
compared to liquid IPV (Fig. 1B), the low average VN-titer of type 3gen composition (DU/mL), D-antigen recovery and residual moisture content (RMC) of
2 was determined as well. Relative rat potency values and lower and upper limits (95%
Type 2 Type 3
37 ± 5 138 ± 5
78 ± 10 75 ± 3
34 ± 2 126 ± 4
86 ± 4 77 ± 3






































45 human dose (panel A) or 1/15 human dose (panel B) of liquid IPV (L IPV, in black)
at 45 C. Individual VN titers specific for serotype 1 (circles), 2 (triangles) and 3
owed 95% confidence interval (CI) values. Asterisks indicate significant differences
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uid IPV.
In general, at temperatures of 37 C and 45 C, the recovery of
type 1-3 D-antigen was lower in liquid IPV than in IPV-LYO (see
Fig. 2). After four weeks storage at 25 C, the rat potency of liquid
IPV was approximately 1 for all serotypes, whereas significantly
lower potency values were observed after short-term storage at
37 C or 45 C (see Fig. 2A). In contrast, IPV-LYO maintained its
potency after short-term storage at 25–45 C.
Even after storage for up to 6 months at 2–8 C or 25 C, no fur-
ther decrease in potency was observed in case of IPV-LYO (see
Fig. 2B).
During 6 months of storage at 37 C, liquid IPV showed no mea-
surable D-antigen recovery and the rat potency was almost com-A
B
Fig. 2. Rat potency of liquid IPV (L IPV) and IPV-LYO after incubation for a short period o
time (6 months at 4 C, 25 C or 37 C) (panel B). The rat potency is calculated based onpletely lost, whereas IPV-LYO still showed D-antigen recoveries
of 39 ± 4%, 122 ± 11% and 73 ± 4%, respectively for type 1, 2 and
3, and significantly higher rat potency values than liquid IPV (see
Fig. 2B).
The rat potency of polio type 3 in IPV-LYO was consistently 2 to
3-fold lower than anticipated as based on the recovered D-antigen
percentage (see Fig. 2A and B).
3.3. Thermostability of polio type 3 in reconstituted IPV-LYO
To examine whether IPV-LYO (type 3) after reconstitution was
more vulnerable to higher temperatures than liquid IPV, a ther-
mostability experiment was performed using reconstituted IPV-
LYO, and both formulated liquid IPV and liquid IPV as controls.f time; 2 weeks at 45 C or one month at 25 C or 37 C (panel A), or long period of
a theoretical composition of 40, 8, 32 DU for type 1, 2, and 3, respectively.
4576 H. Kraan et al. / Vaccine 34 (2016) 4572–4578An incubation period of 24 h at either 4 C or 37 C did not
result in a difference between the samples (see Fig. 3A–C). How-
ever, at 45 C the D-antigen recovery of liquid IPV was clearly
lower than the formulated liquid IPV, and resuspended IPV-LYO.
From Fig. 3C it is clear that freeze-drying and resuspension ren-
dered a type 3 particle characterized by less thermoresistance
(recovery 33%) than its formulated counterpart (recovery 71%).
Such a difference was not observed in case of polio serotype 1
and 2 (see Fig. 3A and B). From these findings it is hypothesized
that the type 3 particle was altered by the lyophilization process
rendering type 3 with a lower thermostability and a lower specific
immunogenicity.3.4. Effect of thimerosal containing pentavalent vaccine on IPV-LYO
Reconstitution of IPV-LYO with pentavalent vaccine (0.005% thi-
merosal, TM) resulted in an evident negative trend in D-antigen
recovery (see Fig. 4). The control, IPV-LYO reconstituted with ultra-
pure water, showed either no (in case of type 1 and 2) or a minimal
loss (in case of type 3) in D-antigen recovery during incubation for
24 h at 37 C.
The negative effect of TM on polio D-antigen was increased at a































































Fig. 3. Stability of reconstituted IPV-LYO. Liquid IPV (L IPV, black bars), formulated
(liquid) IPV prior to lyophilization (L IPV:form, striped bars), and reconstituted IPV-
LYO (red bars) were incubated for 24 h at 4 C, 37 C or 45 C. Subsequently, D-
antigen recoveries were determined by ELISA, specific for type 1 (panel A), type 2
(panel B) and type 3 (panel C), and normalized for D-antigen recoveries directly
after lyophilization. Mean values (n = 3) and SD are shown.25 C (relevant conditions for the WHO open vial policy), there was
already a marked (and unacceptable) loss of 20% in case of type 2
and 3 and 60% in case of type 1.
A similar drop in D-antigenicity was observed when incubating
IPV-LYO with 0.005% TM solution (data not shown) indicating that
the negative effect on D-antigen recovery of IPV-LYO was most
likely caused by the presence of TM.3.5. Effect of pentavalent vaccine on IPV-LYO after pre-incubation with
L-cysteine
Low molecular weight thiols are well known for the ability to
scavenge mercury and/or mercury containing compounds such as
TM [10,11]. Therefore, pentavalent vaccine was pre-incubated with
the TM-scavenger L-cysteine and was used thereafter to reconsti-
tute IPV-LYO. Fig. 5A shows a small initial loss of the D-antigen
recovery upon reconstituting IPV-LYO with pentavalent vaccine.
This initial loss is absent in samples that are reconstituted with
purified water or in samples in which TM was scavenged.
After 24 h at 37 C there is almost no recoverable D-antigen
in case pentavalent vaccine was used to resuspend IPV-LYO
(see Fig. 5B). However, when IPV-LYO was reconstituted with
L-cysteine containing pentavalent vaccine, D-antigen could be
clearly be recovered, values were 61 ± 7%, 107 ± 2% and 96 ± 4%
for type 1, 2 and 3, respectively.4. Discussion
4.1. Detrimental effect of lyophilization on the rat potency of polio
type 3
For release of inactivated polio vaccines two assays are avail-
able: an ELISA for determining the D-antigen concentration (anti-
genicity) and the rat potency test for determining the relative rat
potency (immunogenicity). The European Pharmacopoeia (EP)
allows to omit the rat potency test and to rely exclusively on the
more accurate D-antigen ELISA. Hence, there should be a relation-
ship between the in vitro and in vivo test, despite the considerable
test variation in the rat potency test. Remarkably, in our study the
in vitro test content was not predictable for the immunogenicity of
IPV-LYO type 3 (contrary to the normal in vitro – in vivo relation-
ship observed with type 1 and 2). The type 3 rat potency in IPV-
LYO was 2 to 3-fold lower than anticipated as based on the mea-
sured D-antigen concentration. Earlier studies reported significant
lower virus-neutralizing titers against type 3 in rats immunized
with lyophilized IPV formulated in dissolvable mini-implants (bio-
needles) [12] or weaker serological responses to IPV type 3 after
microneedle patch vaccination of rhesus macaques compared to
intramuscular injection [13].
The use of certain site-specific monoclonal antibodies in the
ELISA is critical for the antigenicity-immunogenicity relation [9].
In the case of detection of polio serotype 3, it has been recom-
mended to include measurement of antigenic site 1, because dis-
ruption of this site strongly diminishes the rat potency [9]. No
evidence for antigenic site 1 disruption was observed in this study.
However, by performing accelerated stability testing it was
revealed that freeze-drying and reconstitution reduced the ther-
mostability of polio type 3 and did not affect the thermostability
of type 1 and 2.
The information on the thermostability and the rat potency of
polio type 3 taken together suggested that lyophilization resulted
in an altered type 3 particle. The nature of this particle remains
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Fig. 4. Effect of pentavalent vaccine on IPV-LYO. IPV-LYO was reconstituted with pentavalent vaccine containing 0.005% of thimerosal at temperatures of 2-8 C (closed
circles, grey), 25 C (closed squares, blue) or 37 C (closed triangles, red) for up to 24 h. Subsequently, D-antigen recoveries were determined by ELISA, specific for type 1
(panel A), type 2 (panel B) and type 3 (panel C). Mean values (n = 3) and SD are shown.
H. Kraan et al. / Vaccine 34 (2016) 4572–4578 4577This study shows that accelerated stability might be of use to
obtain a more reliable prediction of the rat potency of dried IPV
in general.
Interestingly, improved thermostability was observed in formu-
lated liquid IPV compared to conventional liquid IPV without extra
excipients. This indicates that it is possible to stabilize polio D-
antigen in the liquid state by the addition of excipients.
4.2. Use of IPV-LYO in a hexavalent vaccine: overcoming the
detrimental effect of thimerosal
The current study investigated the possible use of lyophilized
IPV as a component for mixing with a pentavalent vaccine
(DTwP-Hib-HBV) thereby forming a hexavalent mixture. Theselicensed pentavalent vaccines all contain traces of thimerosal
(TM), an organomercury compound known for its antiseptic and
antifungal properties. Unfortunately TM may also negatively affect
the antigenicity and immunogenicity of IPV [2]. Within hours after
reconstitution of IPV-LYO with pentavalent vaccine (containing
0.005% TM), a strong reduction in D-antigenicity was observed.
The antigenicity decrease was even more evident when the vaccine
was kept at 37 C showing that also immediate IM-delivery, after
mixing IPV-LYO and pentavalent vaccine, is probably not a feasible
option to mitigate the negative impact of TM on polio D-antigen,
which is consistent with reported findings [2].
Pre-incubation of the TM-containing pentavalent vaccine with
L-cysteine reduced the negative effect of TM on D-antigenicity of
IPV-LYO after reconstitution with pentavalent vaccine. The use of








































Type 1 Type 2 Type 3
A
B
Fig. 5. Effect of cysteine on the stability of IPV-LYOmixed with pentavalent vaccine.
IPV-LYO was mixed with pentavalent vaccine pre-incubated for one hour in the
absence or presence of L-cysteine. Subsequently, D-antigen recoveries directly after
mixing (panel A) and after 24 h incubation at 37 C (panel B) were determined by
ELISA, specific for type 1 (black bars), type 2 (striped bars) and type 3 (red bars), and
normalized for D-antigen recoveries of IPV-LYO prior to mixing and incubation.
Mean values (n = 3) and SD are shown.
4578 H. Kraan et al. / Vaccine 34 (2016) 4572–4578L-cysteine for neutralization of TM in a pentavalent vaccine has not
been published before. However, the use of L-cysteine as a TM-
scavenger is well-known [10,11,14]. The use of compounds, which
compete with polio D-antigen for binding to TM or stabilize IPV,
might offer a potential step towards a TM-resistant IPV formula-
tion (mix-and-shoot approach), which can be used as a component
in a hexavalent vaccine. On the other hand, removing TM com-
pletely from the vaccine may be considered as well by, for exam-
ple, reformulating wP (prior to using it for preparing a
pentavalent mixture).
5. Conclusion
This research demonstrated a clear difference in rat potency
between IPV-LYO and liquid IPV serotype 3. The reduced ther-
mostability of type 3 in IPV-LYO after reconstitution suggestedthe formation of an altered type 3 particle during the lyophilization
process.
Use of IPV-LYO as a component in a hexavalent vaccine by mix-
ing with licensed pentavalent vaccine (DTwP-Hib-HBV) requires
neutralization of TM, by for example L-cysteine, to avoid the dam-
aging effect on polio D-antigen (mix-and-shoot approach).
Further formulation development is needed, in which screening
based on D-antigen thermostability is included, to improve the
potency of IPV-LYO type 3.
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